SCHEMBL4946473

SCHEMBL4946473

CC(C)(C)Oc1ccc(C[C@H](N)C(N)=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.52
ACACB O00763 4/20 0.52
SCN10A Q9Y5Y9 1/20 0.43
EPHX1 P07099 2/20 0.42
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
SLC7A5 Q01650 3/20 0.41
LDHA P00338 1/20 0.40
ALPI P09923 1/20 0.40
PKM P14618 1/20 0.40
PTGS1 P23219 1/20 0.40
XIAP P98170 1/20 0.40
TPH1 P17752 1/20 0.39
GRB2 P62993 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4946470 1.00 PTPN1 (0.52) PTPN1ACACBSCN10AEPHX1PPARA
SCHEMBL17658724 0.89 PTPN1 (0.54) PTPN1ACACBPPARAPPARGITGB3
SCHEMBL2867832 0.87 PTPN1 (0.68) PTPN1ACACBPPARGITGB3ITGA2B
SCHEMBL2118353 0.87 PTPN1 (0.68) PTPN1ACACBPPARGITGB3ITGA2B
SCHEMBL1258519 0.87 PTPN1 (0.68) PTPN1ACACBPPARGITGB3ITGA2B
Hydrochloric Acid SCHEMBL2309162 0.86 PTPN1 (0.67) PTPN1ACACBITGB3ITGA2BSLC7A5
SCHEMBL3729750 0.84 ACACB (0.50) PTPN1ACACBPPARAPPARGITGB3
SCHEMBL4472407 0.84 ACACB (0.53) PTPN1ACACBPPARAPPARGITGB3
SCHEMBL2058886 0.84 ACACB (0.53) PTPN1ACACBPPARAPPARGITGB3
SCHEMBL2311151 0.84 ACACB (0.50) PTPN1ACACBPPARAPPARGITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 WO disclosed
US-7456201-B2 Pharmaceutically active compounds and methods of use LABORATOIRES SERONO SA (CH) 2008-11-25 US disclosed
EP-1441724-B8 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS SERONO LAB (CH) 2007-10-17 EP disclosed
EP-1441724-B1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS APPLIED RESEARCH SYSTEMS (AN) 2007-09-05 EP disclosed
EP-1282418-B1 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY APPLIED RESEARCH SYSTEMS (AN) 2005-08-17 EP disclosed
US-6914069-B2 Pharmaceutically active compounds and methods of use APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-05 US disclosed
US-20050026985-A1 Pharmaceutically active compounds and methods of use APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 2005-02-03 US disclosed
US-20040198799-A1 Methods of increasing endogenous testosterone levels LABORATOIRES SERONO SA (CH) 2004-10-07 US disclosed
EP-1441724-A1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS Applied Research Systems ARS Holding S.A. (AN) 2004-08-04 EP disclosed
WO-2003026649-A1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-04-03 WO disclosed
EP-1282418-A2 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY Serono Reproductive Biology Institute, Inc. (US) 2003-02-12 EP disclosed
US-20020132844-A1 Pharmaceutically active compounds and methods of use MERCK SERONO SA (CH) 2002-09-19 US disclosed
WO-2001087287-A2 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198799-A1 Methods of increasing endogenous testosterone levels SHBG, CYP17A1, NR5A1 PTPN1 4222/4885ACACB 1054/4885SCN10A 3779/4885
US-20020132844-A1 Pharmaceutically active compounds and methods of use CATSPER1, NASP, ACR PTPN1 3403/4885ACACB 1296/4885SCN10A 3547/4885
US-20050026985-A1 Pharmaceutically active compounds and methods of use CATSPER1, NASP, ACR PTPN1 3403/4885ACACB 1296/4885SCN10A 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.